CompletedPhase 4NCT02214615
Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations
Studying Primary erythromelalgia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- VA Connecticut Healthcare System
- Principal Investigator
- Stephen Waxman, MD, PhDVAMC West Haven and Yale University
- Intervention
- Carbamazepine(drug)
- Enrollment
- 2 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2014 – 2016
Study locations (2)
- Yale University, New Haven, Connecticut, United States
- VA Connecticut Healthcare System, West Haven, Connecticut, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02214615 on ClinicalTrials.govOther trials for Primary erythromelalgia
Additional recruiting or active studies for the same condition.